Literature DB >> 19202044

Drug incompatibility chemistry.

David W Newton1.   

Abstract

PURPOSE: The chemical interactions that cause drug incompatibility in solutions, with emphasis on the acid-base and ionized-nonionized forms of organic, weak, electrolyte drugs, are examined.
SUMMARY: When the dilution or mixing of the salt or ionized forms of organic drugs results in precipitation, the most likely cause is formation of the nonionized drug forms. More than 90% of drugs are organic, weak electrolytes, especially those compounded, manufactured, or reconstituted as injections in predominantly ionized or salt forms. Acid-base reactions are the most common causes of drug incompatibility as precipitation of nonionized drug forms. Precipitation is likely when oppositely charged, organic drug ions that contain aromatic rings are combined in relatively strong concentrations. Salts of polyvalent anions and cations are generally less soluble than salts in which both ions are monovalent or in which one ion is monovalent and its opposite ion is polyvalent. The most clinically important potential precipitates among these ions are dibasic and monohydrogen calcium phosphate.
CONCLUSION: Incompatibility of drug and nutrient injections is clinically hazardous. Knowledge of products' chemical facts, organic acid-base equilibria in relation to ionization and nonionization and aqueous solubility, and ranges of pH and ingredient strength from United States Pharmacopeia monographs and product labeling is the foundation of expertise in drug incompatibility. Precipitation in injectable drug solutions should be suspected, particularly when oppositely charged drug salts are mixed in relatively strong concentrations and when pH values of dilutions create more than 1% of nonionized drug forms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19202044     DOI: 10.2146/ajhp080059

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  20 in total

1.  Creation of medicinal chemistry learning communities through enhanced technology and interdisciplinary collaboration.

Authors:  Brian Henriksen; Victoria Roche
Journal:  Am J Pharm Educ       Date:  2012-10-12       Impact factor: 2.047

2.  Drug incompatibilities in the adult intensive care unit of a university hospital.

Authors:  Naiane Roveda Marsilio; Daiandy da Silva; Denise Bueno
Journal:  Rev Bras Ter Intensiva       Date:  2016-06

3.  Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story?

Authors:  Wesley D Kufel; Christopher D Miller; Paul R Johnson; Kaleigh Reid; James J Zahra; Robert W Seabury
Journal:  Hosp Pharm       Date:  2017-02

4.  Piper betle leaf extract enhances the cytotoxicity effect of 5-fluorouracil in inhibiting the growth of HT29 and HCT116 colon cancer cells.

Authors:  Pek Leng Ng; Nor Fadilah Rajab; Sue Mian Then; Yasmin Anum Mohd Yusof; Wan Zurinah Wan Ngah; Kar Yong Pin; Mee Lee Looi
Journal:  J Zhejiang Univ Sci B       Date:  2014-08       Impact factor: 3.066

5.  [Precipitation of piritramide and cefazolin. Study of the dependence on concentration and pH].

Authors:  V-S Eckle; C Grasshoff
Journal:  Anaesthesist       Date:  2013-11-14       Impact factor: 1.041

6.  Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery.

Authors:  Hilary M Teibel; Chad A Knoderer; Kristen R Nichols
Journal:  Hosp Pharm       Date:  2015-09-16

7.  Combination therapies in ophthalmology: implications for intravitreal delivery.

Authors:  Gholam A Peyman; Kamran Hosseini
Journal:  J Ophthalmic Vis Res       Date:  2011-01

8.  Making the Medicine Go Down: Salt or Sugar?

Authors:  Ryan M Brown; Joanna L Stollings; Matthew W Semler
Journal:  Crit Care Med       Date:  2018-08       Impact factor: 7.598

9.  Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility.

Authors:  Aurélie Foinard; Bertrand Décaudin; Christine Barthélémy; Bertrand Debaene; Pascal Odou
Journal:  Ann Intensive Care       Date:  2012-07-13       Impact factor: 6.925

10.  Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations.

Authors:  Kristen R Nichols; Michael W Demarco; Michael D Vertin; Chad A Knoderer
Journal:  Hosp Pharm       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.